{"id":"infliximab-subcutaneous","safety":{"commonSideEffects":[{"rate":null,"effect":"Infections (including serious infections)"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Upper respiratory tract infections"},{"rate":null,"effect":"Tuberculosis reactivation"},{"rate":null,"effect":"Malignancy risk"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By blocking TNF-α, infliximab reduces inflammatory signaling and immune activation in conditions driven by excessive TNF production. The subcutaneous formulation allows for patient self-administration and may improve convenience compared to intravenous dosing. This mechanism is effective in autoimmune and inflammatory diseases where TNF-α plays a central pathogenic role.","oneSentence":"Infliximab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), a key inflammatory cytokine.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:16:03.137Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Crohn's disease"},{"name":"Ulcerative colitis"},{"name":"Ankylosing spondylitis"},{"name":"Psoriatic arthritis"},{"name":"Plaque psoriasis"}]},"trialDetails":[{"nctId":"NCT03596645","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2018-10-29","conditions":"Colitis, Ulcerative","enrollment":84},{"nctId":"NCT06941376","phase":"PHASE2","title":"An Open-Label Study of Effectiveness of Immunomodulatory Medications for Patients With Relapsing Polychondritis","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2025-08-01","conditions":"Relapsing Polychondritis","enrollment":20},{"nctId":"NCT07344428","phase":"NA","title":"Efficacy and Safety of CDED With Anti-TNF-α Biologics in Crohn's Disease: A Randomized Trial","status":"NOT_YET_RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2026-02-01","conditions":"Crohn's Disease；Mucosal Healing；Dietary Intervention","enrollment":185},{"nctId":"NCT06381518","phase":"NA","title":"Switching From Intravenous to Subcutaneous Infliximab in Adult Patients With Inflammatory Bowel Disease","status":"COMPLETED","sponsor":"Zuyderland Medisch Centrum","startDate":"2024-03-12","conditions":"IBD, Infliximab, Crohn Disease","enrollment":38},{"nctId":"NCT05424926","phase":"","title":"Sub-cutaneous Infliximab in Inflammatory Rheumatic Disease","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-02-24","conditions":"Rheumatoid Arthritis, Spondyloarthritis, Psoriatic Arthritis","enrollment":22},{"nctId":"NCT07120152","phase":"","title":"A Pharmacokinetic-pharmacodynamic Modeling and Simulation Study of Subcutaneous Infliximab in Patients With Inflammatory Bowel Disease","status":"NOT_YET_RECRUITING","sponsor":"Erwin Dreesen","startDate":"2025-09-01","conditions":"IBD - Inflammatory Bowel Disease, RA - Rheumatoid Arthritis","enrollment":439},{"nctId":"NCT07138898","phase":"PHASE2","title":"Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty","status":"NOT_YET_RECRUITING","sponsor":"NYU Langone Health","startDate":"2025-09","conditions":"Rheumatic Disease","enrollment":80},{"nctId":"NCT03679546","phase":"PHASE4","title":"EFFICACI : EFFicacy of Intravenous Infliximab Versus Vedolizumab After Failure of subCutaneous Anti-TNF in Patients With UlCerative Colitis","status":"COMPLETED","sponsor":"Rennes University Hospital","startDate":"2019-01-04","conditions":"Ulcerative Colitis","enrollment":151},{"nctId":"NCT06998797","phase":"","title":"Efficacy of Subcutaneous Infliximab in Acute Severe Ulcerative Colitis: a Multicenter Retrospective Study","status":"NOT_YET_RECRUITING","sponsor":"Central Hospital, Nancy, France","startDate":"2025-06-01","conditions":"Ulcerative Colitis","enrollment":50},{"nctId":"NCT05722353","phase":"NA","title":"IBD Disease Course of Infliximab-naïve IBD Patients Treated With Subcutaneous Infliximab CT-P13 Remsima®","status":"ACTIVE_NOT_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-02-13","conditions":"Inflammatory Bowel Diseases","enrollment":120},{"nctId":"NCT03885713","phase":"PHASE4","title":"Identification of Predictive Biomarkers for Response to Biologic Therapies and Tofacitinib in Inflammatory Bowel Disease","status":"COMPLETED","sponsor":"Fundación de Investigación Biomédica - Hospital Universitario de La Princesa","startDate":"2019-09-10","conditions":"Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis","enrollment":180},{"nctId":"NCT05169593","phase":"PHASE4","title":"Prevention of Postoperative Endoscopic Recurrence with Endoscopy-driven Versus Systematic Biological Therapy","status":"RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2022-09-08","conditions":"Crohn Disease","enrollment":292},{"nctId":"NCT06059989","phase":"PHASE3","title":"InDuctIon TREatment with SubCuTaneous Infliximab for Crohn's Disease","status":"RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2021-11-25","conditions":"Inflammatory Disease, Disease Crohn, Bowel Disease","enrollment":158},{"nctId":"NCT03445845","phase":"PHASE4","title":"Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial Spondyloarthritis","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2018-12-14","conditions":"Axial Spondyloarthritis","enrollment":300},{"nctId":"NCT06604728","phase":"","title":"Effectiveness and Tolerance of IV vs SC Biological Drugs in Gastrointestinal Diseases","status":"RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2023-09-04","conditions":"Inflammatory Bowel Diseases","enrollment":400},{"nctId":"NCT06591273","phase":"PHASE1, PHASE2","title":"Efficacy and Safety of Infliximab Biosimilar in Treatment of Moderate to Severe Psoriasis; A Single-arm Clinical Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Services Institute of Medical Sciences, Pakistan","startDate":"2023-11-06","conditions":"Moderate to Severe Chronic Plaque Psoriasis","enrollment":104},{"nctId":"NCT06274294","phase":"PHASE3","title":"Pharmacokinetics, Efficacy and Safety of CT-P13 Subcutaneous as Induction Therapy in Patients With Active CD or UC","status":"UNKNOWN","sponsor":"CMC Ambroise Paré","startDate":"2024-07-10","conditions":"Inflammatory Bowel Diseases","enrollment":130},{"nctId":"NCT04725422","phase":"","title":"CHronic Nonbacterial Osteomyelitis International Registry","status":"RECRUITING","sponsor":"Seattle Children's Hospital","startDate":"2018-08-01","conditions":"Chronic Nonbacterial Osteomyelitis, Chronic Recurrent Multifocal Osteomyelitis","enrollment":2000},{"nctId":"NCT06113913","phase":"PHASE4","title":"Subcutaneous Infliximab After A Previous Intravenous Dose Optimization","status":"RECRUITING","sponsor":"Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW","startDate":"2024-04-09","conditions":"Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis","enrollment":275},{"nctId":"NCT06064864","phase":"NA","title":"Efficacy and Safety of Formulation Switching Between SC Infliximab and IV Infliximab in Patients With CD","status":"RECRUITING","sponsor":"Asan Medical Center","startDate":"2023-10-09","conditions":"Crohn's Disease","enrollment":100},{"nctId":"NCT01793519","phase":"PHASE4","title":"Stopping TNF Alpha Inhibitors in Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"Georgetown University","startDate":"2013-01","conditions":"Rheumatoid Arthritis","enrollment":290},{"nctId":"NCT04990258","phase":"","title":"A 24-month Real Life PErsistence Efficacy and Safety Study in IBD Patients in REMission Switched From Intravenous Infliximab to Subcutaneous Infliximab CT-P13 Remsima®SC","status":"UNKNOWN","sponsor":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives","startDate":"2021-09-06","conditions":"Inflammatory Bowel Diseases","enrollment":444},{"nctId":"NCT05663268","phase":"EARLY_PHASE1","title":"Efficacy and Safety of Infliximab Biosimilar in the Treatment of Resistant Hidradenitis Suppurativa","status":"COMPLETED","sponsor":"Services Institute of Medical Sciences, Pakistan","startDate":"2022-10-01","conditions":"Hidradenitis Suppurativa","enrollment":37},{"nctId":"NCT03945019","phase":"PHASE3","title":"CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Crohn's Disease (LIBERTY-CD)","status":"COMPLETED","sponsor":"Celltrion","startDate":"2019-10-28","conditions":"Crohn's Disease","enrollment":396},{"nctId":"NCT04205643","phase":"PHASE3","title":"CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Ulcerative Colitis (LIBERTY-UC)","status":"COMPLETED","sponsor":"Celltrion","startDate":"2020-09-01","conditions":"Ulcerative Colitis","enrollment":548},{"nctId":"NCT02994836","phase":"PHASE4","title":"GIS-SUSANTI-TNF-2015 (Anti-TNF Discontinuation )","status":"COMPLETED","sponsor":"Fundación de Investigación Biomédica - Hospital Universitario de La Princesa","startDate":"2017-04-21","conditions":"Crohn's Disease, Inflammatory Bowel Disease, Ulcerative Colitis","enrollment":139},{"nctId":"NCT05584228","phase":"NA","title":"Medical Treatment Versus Surgery in Stricturing Small Bowel Crohn's Disease","status":"NOT_YET_RECRUITING","sponsor":"Nantes University Hospital","startDate":"2023-04-01","conditions":"Crohn Disease","enrollment":150},{"nctId":"NCT05072782","phase":"PHASE4","title":"Management of Moderate POstoperative Recurrence in Crohn's Disease: a randoMizEd contROLled Trial of Therapeutic Escalation, the POMEROL Trial. (POMEROL)","status":"UNKNOWN","sponsor":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives","startDate":"2021-12-21","conditions":"Crohn Disease","enrollment":360},{"nctId":"NCT04378621","phase":"NA","title":"Effect of Antiinflammatory Treatment Versus Hand Training on Neuropsychiatric Comorbidity in RA-patients","status":"UNKNOWN","sponsor":"Vastra Gotaland Region","startDate":"2020-10-01","conditions":"Rheumatoid Arthritis, Pain, Fatigue","enrollment":212},{"nctId":"NCT01971970","phase":"","title":"Biomarkers of Anti-TNF Treatment in Inflammatory Bowel Disease (IBD)","status":"COMPLETED","sponsor":"Erasmus Medical Center","startDate":"2013-10","conditions":"Inflammatory Bowel Diseases","enrollment":45},{"nctId":"NCT03269695","phase":"PHASE2","title":"Efficacy, Safety and Tolerability of PF-06687234 as Add-on Therapy to Infliximab in Active UC Subjects Not in Remission.","status":"TERMINATED","sponsor":"Pfizer","startDate":"2017-12-20","conditions":"Ulcerative Colitis","enrollment":20},{"nctId":"NCT05164198","phase":"PHASE4","title":"REduCed Dose of TNFi in Patients With Ankylosing SpondyliTis (RECAST)","status":"UNKNOWN","sponsor":"Hanyang University Seoul Hospital","startDate":"2022-01-15","conditions":"Ankylosing Spondylitis, Axial Spondyloarthritis","enrollment":448},{"nctId":"NCT02136069","phase":"PHASE3","title":"A Study Comparing the Efficacy and Safety of Etrolizumab to Infliximab in Participants With Moderate to Severe Ulcerative Colitis Who Are Naïve to Tumor Necrosis Factor (TNF) Inhibitors","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-12-24","conditions":"Ulcerative Colitis","enrollment":397},{"nctId":"NCT05071404","phase":"","title":"Efficacy Assessment and Monitoring of Subcutaneous Infliximab Levels.","status":"COMPLETED","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2020-11-01","conditions":"Inflammatory Bowel Diseases","enrollment":17},{"nctId":"NCT00237484","phase":"PHASE3","title":"Effect of Infliximab on the Efficacy of Peg-Intron/Ribavirin in Patients With Hepatitis C (Study P04257AM4)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-07-18","conditions":"Hepatitis C, Chronic","enrollment":89},{"nctId":"NCT02883452","phase":"PHASE1","title":"A Phase I Study to Evaluate Pharmacokinetics, Efficacy and Safety of CT-P13 Subcutaneous in Patients With Active Crohn's Disease and Ulcerative Colitis","status":"COMPLETED","sponsor":"Celltrion","startDate":"2016-09-29","conditions":"Crohn's Disease, Ulcerative Colitis (Part 2 Only)","enrollment":181},{"nctId":"NCT03147248","phase":"PHASE3","title":"A Phase I/III Study to Evaluate Efficacy, PK and Safety Between CT-P13 SC and CT-P13 IV in Patients With Active RA","status":"COMPLETED","sponsor":"Celltrion","startDate":"2016-09-12","conditions":"Rheumatoid Arthritis","enrollment":407},{"nctId":"NCT02413047","phase":"NA","title":"Evaluate if Response to Infliximab or Adalimumab May be Regained With an Immunomodulator","status":"TERMINATED","sponsor":"Indiana University","startDate":"2015-05","conditions":"Inflammatory Bowel Disease, Ulcerative Colitis, Crohn's Disease","enrollment":3},{"nctId":"NCT03446976","phase":"PHASE1","title":"CT-P13 (Infliximab) Subcutaneous Administration by Pre-filled Syringe and Auto-injector in Healthy Subjects","status":"COMPLETED","sponsor":"Celltrion","startDate":"2018-02-21","conditions":"Health, Subjective","enrollment":218},{"nctId":"NCT00514982","phase":"PHASE2","title":"Medical Treatment of Colitis in Patients With Hermansky-Pudlak Syndrome","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2007-08-07","conditions":"Hermanski-Pudlak Syndrome, Colitis, Cytokines","enrollment":""},{"nctId":"NCT01295151","phase":"PHASE4","title":"SWITCH Clinical Trial for Patients With Rheumatoid Arthritis Who Have Failed an Initial TNF-blocking Drug.","status":"COMPLETED","sponsor":"Julia Brown","startDate":"2011-08","conditions":"Rheumatoid Arthritis","enrollment":122},{"nctId":"NCT01004432","phase":"PHASE3","title":"Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)","status":"COMPLETED","sponsor":"Janssen Biotech, Inc.","startDate":"2009-12","conditions":"Arthritis, Arthritis, Rheumatoid, Autoimmune Diseases","enrollment":433},{"nctId":"NCT01233583","phase":"","title":"Regulatory T-cells in Psoriasis Patients as Targets for Therapy","status":"COMPLETED","sponsor":"University of Aberdeen","startDate":"2010-06","conditions":"Psoriasis","enrollment":38},{"nctId":"NCT00207714","phase":"PHASE2","title":"An Efficacy and Safety Study of CNTO 148 Subcutaneous Injection Compared With Placebo in Patients With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"2003-11","conditions":"Rheumatoid Arthritis","enrollment":172},{"nctId":"NCT00307931","phase":"PHASE3","title":"Certolizumab Pegol for Treatment of Adult Greek Patients With Moderate to Severe Crohn's Disease Who Failed Infliximab","status":"TERMINATED","sponsor":"UCB Pharma","startDate":"2007-04","conditions":"Crohn's Disease","enrollment":16},{"nctId":"NCT01237262","phase":"PHASE4","title":"Evaluation of Lymphocytic Infiltrate, Dendritic Cells and Cytokines Expression in Psoriatic Lesion and Normal Skin Before and After TNF Alfa Inhibitors Therapy","status":"UNKNOWN","sponsor":"University of Padova","startDate":"2010-11","conditions":"Moderate to Severe Psoriasis., Absolute Number, Density of Immune Infiltrate and Dendritic Cells and Inflammatory Cytokines Expression Pattern.","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Remsima 120mg solution s.c."],"phase":"phase_3","status":"active","brandName":"Infliximab subcutaneous","genericName":"Infliximab subcutaneous","companyName":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","companyId":"academisch-medisch-centrum-universiteit-van-amsterdam-amc-uva","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Infliximab is a subcutaneous medication used to treat conditions such as Relapsing Polychondritis, Inflammatory Bowel Disease, Ulcerative Colitis, Crohn's Disease, and Inflammatory Bowel Diseases. It works as a TNF-alpha inhibitor, belonging to the class of INHIBITOR drugs, which are antibody-based medications that target tumor necrosis factor.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}